AOA-2 Derivatives as Outer Membrane Protein A Inhibitors for Treatment of Gram-Negative Bacilli Infections.

dc.contributor.authorAyerbe-Algaba, Rafael
dc.contributor.authorBayó, Nuria
dc.contributor.authorVerdú, Ester
dc.contributor.authorParra-Millán, Raquel
dc.contributor.authorSeco, Jesús
dc.contributor.authorTeixidó, Meritxell
dc.contributor.authorPachón, Jerónimo
dc.contributor.authorGiralt, Ernest
dc.contributor.authorSmani, Younes
dc.date.accessioned2025-01-07T15:45:10Z
dc.date.available2025-01-07T15:45:10Z
dc.date.issued2021-02-12
dc.description.abstractPreviously, we identified that a cyclic hexapeptide AOA-2 inhibited the interaction of Gram-negative bacilli (GNB) like Acinetobacter baumannii, Pseudomonas aeruginosa, and Escherichia coli to host cells thereby preventing the development of infection in vitro and in a murine sepsis peritoneal model. In this work, we aimed to evaluate in vitro a library of AOA-2 derivatives in order to improve the effect of AOA-2 against GNB infections. Ten AOA-2 derivatives were synthetized for the in vitro assays. Their toxicities to human lung epithelial cells (A549 cells) for 24 h were evaluated by determining the A549 cells viability using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The effect of these peptide derivatives and AOA-2 at 250, 125, 62.5, and 31.25 μg/mL on the attachment of A. baumannii ATCC 17978, P. aeruginosa PAO1 and E. coli ATCC 25922 strains to A549 cells was characterized by adherence and viability assays. None of the 10 derivatives showed toxicity to A549 cells. RW01 and RW06 have reduced more the adherence of ATCC 17978, PAO1 and ATCC 2599 strains to A549 cells when compared with the original compound AOA-2. Moreover, both peptides have increased slightly the viability of infected A549 cells by PAO1 and ATCC 25922 than those observed with AOA-2. Finally, RW01 and RW06 have potentiated the activity of colistin against ATCC 17978 strain in the same level with AOA-2. The optimization program of AOA-2 has generated two derivatives (RW01 and RW06) with best effect against interaction of GNB with host cells, specifically against P. aeruginosa and E. coli.
dc.identifier.doi10.3389/fmicb.2021.634323
dc.identifier.issn1664-302X
dc.identifier.pmcPMC7907166
dc.identifier.pmid33643267
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7907166/pdf
dc.identifier.unpaywallURLhttps://www.frontiersin.org/articles/10.3389/fmicb.2021.634323/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27372
dc.journal.titleFrontiers in microbiology
dc.journal.titleabbreviationFront Microbiol
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.organizationInstituto de Investigación Biomédica de Sevilla (IBIS)
dc.page.number634323
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAOA-2 derivatives
dc.subjectGram-negative bacilli
dc.subjectinhibitor
dc.subjectouter membrane protein A
dc.subjectpeptides
dc.titleAOA-2 Derivatives as Outer Membrane Protein A Inhibitors for Treatment of Gram-Negative Bacilli Infections.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number12

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC7907166.pdf
Size:
1020.39 KB
Format:
Adobe Portable Document Format